

**1 April 2022**

## **Experienced dermatology executives join Botanix**

**Philadelphia PA and Phoenix USA, 1 April 2022:** Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), is pleased to announce that experienced dermatology executives Howie McKibbon and Dr Patricia Walker have joined Botanix. Mr McKibbon joins as Chief Commercial Officer and Dr Walker joins as Chief Medical Adviser.

Howie has more than 20 years of leadership experience in the pharmaceutical industry and most recently served as the Senior Vice-President, Worldwide Commercial Operations at Dermavant Science, where he was responsible for all Commercial activity and played a major role in building the company and acquiring the flagship psoriasis product tapinarof. Prior to that, he was the Senior-Vice President, Sales and Marketing at Anacor Pharmaceuticals, a dermatology-focused biopharmaceutical company where he built the Sales, Marketing, Managed Markets, Market Access and Trade functions working alongside Botanix President, Vince Ippolito. Prior to Anacor, Howie was the Vice-President, Dermatology and Immunology at Medicis Pharmaceuticals an industry-leading dermatology company. His background also includes commercial leadership positions across portfolios of neuroscience and oncology brands from launch to exclusivity at Cephalon and Wyeth Pharmaceuticals.

Over the course of his career Howie has launched 15 products including 11 in dermatology. He has managed over 30 dermatology products and played a significant role in two of the largest dermatology acquisitions with combined valuations of \$7.8 billion. He holds a B.A. in History from the University of South Florida, an MBA from Mercer University’s Stetson School of Business and Economics and a Doctor of Pharmacy from Mercer University’s Southern School of Pharmacy.

Dr Walker is a board-certified dermatologist specializing in medical and aesthetic dermatology. She is an industry expert and has served in various leadership roles, including President and head of R&D for Brickell Biotech, Chief Medical Officer for Kythera Biopharmaceuticals, Inc., Executive Vice President and Chief Scientific Officer for Allergan Medical Aesthetics and Vice President and Dermatology Therapeutic Area Head at Allergan. Dr. Walker’s clinical and research work has contributed substantially to the world of dermatology.

Over the past 20 years, she has played a key role in the development and approval of key dermatology products including Tazorac®, Botox® Cosmetic, Juvederm™, Hylaform®, Captique®, LAP-BAND®, Inamed® Silicone gel-filled breast implants and Kybella®. Dr. Walker completed her medical degree and dermatology residency training at the University of Iowa College of Medicine. She also completed a research fellowship at the National Institute of Health’s Dermatology Branch.

**Botanix President and Executive Chair Vince Ippolito said:** *"We are very excited to welcome both Howie and Patty to the Company and are very pleased to gain the benefit of their extensive dermatology drug development and commercialisation experience."*

*"Both executives have a tremendous track record in transitioning products from clinical development into FDA approval and commercial launch and they have built teams to support successful development and sales and marketing functions. They are an excellent addition to the team."*

Release authorised by

**Vince Ippolito**

President and Executive Chairman

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology focused company based in Philadelphia and Phoenix (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate development platforms - dermatology and antimicrobial products. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: <http://www.botanixpharma.com/>

### For more information, please contact:

#### General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

#### Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

#### Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

[haley@hck.digital](mailto:haley@hck.digital)

### Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to

change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.